Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

By A. D'Amico, Ming-Hui Chen, A. Renshaw, M. Loffredo, P. Kantoff. Journal of the American Medical Association (JAMA), 2008

731 citations recorded by the source corpus.

Subfields: Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/99f529f054dd22b938c3ec19a2902ff61888aeac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. A. Heidenreich
2. Michel Bolla
3. N. Mottet
4. J. Bellmunt
5. V. Matveev
6. Steven Joniau
7. F. Zattoni
8. Thomas Wiegel

Citations in the corpus

• EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. (2014, background): “For high-risk localized PCa, the combination of EBRT with ADT is highly recommended, as shown by phase 3 randomized trials [96,97], which display a significant improvement in overall survival.”
• Adverse effects of androgen deprivation therapy and strategies to mitigate them. (2015, background): “Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment and has been shown in randomized trials to improve overall survival when used with radiation for intermediate- and high-risk localized disease [1,2], as well as locally advanced [3,4] and node-positive disease [5], and aft”